Kymera Therapeutics, Inc.
KYMRHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Kymera Therapeutics, Inc. (KYMR) is listed under Biotechnology. At a $9.52B market cap, Kymera Therapeutics, Inc. ranks as a mid-cap company within healthcare. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors.
Market Cap
$9.52B
Beta
1.96
P/E (TTM)
—
P/E (Fwd)
-26.63
EPS (TTM)
$-3.63
EPS (Fwd)
$-4.35
ROE
-27.1%
ROA
-17.2%
Cash
$650.9M
Total Debt
$80.5M
Free CF
-$139.3M
52W Change
150.7%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $650.9M in cash comfortably exceeding the $80.5M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$139.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -27.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $46.8M (2022) to $39.2M (2025), a 16% decline worth watching.
Kymera Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing KYMR's risk profile alongside its fundamentals and technical indicators provides a more complete picture.